SCYNEXIS (SCYX) Stock Price, News & Analysis

Company Overview

SCYNEXIS, Inc. is a clinical‐stage biotechnology company dedicated to discovering and developing novel anti‐infective therapies with an initial focus on antifungal treatments. The company’s proprietary platform centers on triterpenoid glucan synthase inhibitors, a mechanism designed to target and disrupt the cell walls of pathogenic fungi. With its lead candidate, ibrexafungerp, SCYNEXIS is pioneering the first approved oral and intravenous agents in a new antifungal class.

Ibrexafungerp (formerly SCY-078) has achieved regulatory approval for the treatment of vulvovaginal candidiasis and is advancing additional indications, including invasive candidiasis and aspergillosis. In parallel, the company is developing rezafungin (CD101), a once‐weekly intravenous echinocandin designed to improve upon existing therapies for serious systemic fungal infections. SCYNEXIS collaborates with contract manufacturing organizations and global clinical research partners to support these programs through pivotal trials and regulatory filings.

Founded in 2009 and headquartered in Research Triangle Park, North Carolina, SCYNEXIS operates a research and development hub focused on antifungal innovation. The company’s development efforts extend across North America, Europe and Asia Pacific, with clinical trial sites in multiple countries and strategic alliances that facilitate manufacturing scale‐up and distribution. Through these partnerships, SCYNEXIS aims to address significant unmet medical needs in immunocompromised patients and those at high risk of fungal infections.

Under the leadership of Paul A. Tcheng, M.D., who serves as President, CEO and Chairman, the company has built a management team with deep expertise in infectious disease drug development, regulatory affairs and commercialization. SCYNEXIS continues to expand its pipeline with next‐generation compounds and anticipates further clinical milestones as it progresses toward broadening patient access to new antifungal therapies.

Key Stats

• Today's Range: $0.70 to $0.75
• 50-Day Range: $0.67 to $0.98
• 52-Week Range: $0.66 to $2.28
• Volume: 147,473 shs
• Average Volume: 166,607 shs
• Market Capitalization: $28.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCYNEXIS Stock Analysis - MarketRank™

SCYNEXIS scored higher than 18% of companies evaluated by MarketBeat, and ranked 859th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SCYNEXIS.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SCYNEXIS has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.63% of the float of SCYNEXIS has been sold short.

Short Interest Ratio / Days to Cover

SCYNEXIS has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in SCYNEXIS has recently decreased by 2.70%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SCYNEXIS does not currently pay a dividend.

Dividend Growth

SCYNEXIS does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.63% of the float of SCYNEXIS has been sold short.

Short Interest Ratio / Days to Cover

SCYNEXIS has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in SCYNEXIS has recently decreased by 2.70%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

SCYNEXIS has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

9 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SCYNEXIS insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.86% of the stock of SCYNEXIS is held by insiders.

Percentage Held by Institutions

54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCYX Stock Analysis - Frequently Asked Questions

How have SCYX shares performed this year?

SCYNEXIS's stock was trading at $1.21 at the beginning of 2025. Since then, SCYX stock has decreased by 40.1% and is now trading at $0.7250.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.14 million. SCYNEXIS had a negative net margin of 1,030.04% and a negative trailing twelve-month return on equity of 53.47%.

When did SCYNEXIS's stock split?

SCYNEXIS's stock reverse split on Friday, July 17th 2020.The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Zomedica (ZOM), Jumia Technologies (JMIA), NIO (NIO), Nano Dimension (NNDM), Sorrento Therapeutics (SRNE), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCYX
• CIK: 1178253
• Web: www.scynexis.com
• Phone: (201) 884-5485
• Fax: 201-884-5490
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.29 million
• Net Margins: -1,030.04%
• Pretax Margin: -1,044.49%
• Return on Equity: -53.47%
• Return on Assets: -32.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.83
• Quick Ratio: 5.83

Sales & Book Value

• Annual Sales: $2.63 million
• Price / Sales: 10.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.45 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 39,020,000
• Free Float: 37,124,000
• Market Cap: $28.09 million
• Optionable: Optionable
• Beta: 1.57